Aug 26, 2020 8:30am EDT CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants
Aug 24, 2020 9:00am EDT CohBar Announces First Subjects Dosed in its Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
Aug 13, 2020 4:03pm EDT CohBar Reports Second Quarter 2020 Financial Results and Provides Business Update
Aug 05, 2020 9:00am EDT CohBar Presents New Antifibrotic Data at the American Thoracic Society’s Virtual 2020 Conference
Jul 30, 2020 9:00am EDT CohBar to Announce 2020 Second Quarter Financial Results and Provide Business Update on August 13, 2020